American Journal of Clinical and Experimental Medicine最新文献_第2页

Performance Evaluation of Machine Learning Methods for Heart Failure Prediction 机器学习方法在心力衰竭预测中的性能评估

American Journal of Clinical and Experimental Medicine Pub Date : 2023-03-31 DOI: 10.11648/j.ajcem.20231102.12

Jing Xia, Xiaoying Wang

{"title":"Performance Evaluation of Machine Learning Methods for Heart Failure Prediction","authors":"Jing Xia, Xiaoying Wang","doi":"10.11648/j.ajcem.20231102.12","DOIUrl":"https://doi.org/10.11648/j.ajcem.20231102.12","url":null,"abstract":": Heart failure is a syndrome of cardiac circulation disorder. Due to the dysfunction of the systolic function or diastolic function of the heart, the venous blood volume cannot be fully discharged from the heart, resulting in blood stasis in the venous system and insufficient perfusion in the arterial system. The symptoms of this disorder are concentrated in pulmonary congestion and vena cava congestion. The correlation between the inducement of heart failure and the incidence of heart failure is a subject that needs to be studied in the medical field. In recent years, with the development of data mining technology, more and more analytical models and algorithms have been applied in the medical field, which greatly improve the efficiency of medical data analysis and enable medical workers to cure diseases better. In this study, an ensemble learning model is applied to analyze the data of heart failure. First, the data is preprocessed and normalized, and features that are not associated with death rate of heart failure are removed. Secondly, multiple base classifiers are trained and compared. Finally, the competent base classifiers are selected and integrated with the Stacking-based ensemble learning algorithm for final classification. Comparative analysis showed that the prediction results of ensemble model are better than that of base classifiers in evaluation indexes such as accuracy, precision, AUC, Balanced accuracy and F1-score for the heart failure data.","PeriodicalId":404444,"journal":{"name":"American Journal of Clinical and Experimental Medicine","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126647495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Papillary Tumor of the Pineal Region: A Case Report and Literature Review 松果体区乳头状肿瘤1例报告及文献复习

American Journal of Clinical and Experimental Medicine Pub Date : 2023-03-20 DOI: 10.11648/j.ajcem.20231102.11

Peng Lilin, Lijuan Zhong, Yang Bo, Yuan-yuan Lu

引用次数: 0

Oblique Lateral Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease: A Meta-Analysis 斜侧腰椎椎间融合术和经椎间孔腰椎椎间融合术治疗腰椎退行性疾病:一项meta分析

American Journal of Clinical and Experimental Medicine Pub Date : 2023-02-21 DOI: 10.11648/j.ajcem.20231101.14

Weibin Liang, Yukun Jia, Kaishuai Zhao, Guangye Wang

引用次数: 0

Coagulation Parameters Among Sudanese Individuals Vaccinated with Johnson and Johnson Vaccine at Khartoum State, 2022 2022年喀土穆州接种强生和强生疫苗的苏丹人的凝血参数

American Journal of Clinical and Experimental Medicine Pub Date : 2023-01-13 DOI: 10.11648/j.ajcem.20231101.13

Nihad Elsadig Babiker, Bashir Ahmed Albashir Ahmed, Faihaa Alhady Alhussien Mohammed, Aamir Yassir Bashir Mohammed, Amna Ibrahim Hroon Abdelrhman, Duaa Adel Abdalrehim, Maye Mohammed Merghani, T. Alabid

引用次数: 0

Ectopic Parathyroid Adenoma in the Framework of an MEN1 mena框架内异位甲状旁腺瘤1

American Journal of Clinical and Experimental Medicine Pub Date : 2023-01-09 DOI: 10.11648/j.ajcem.20231101.11

Meriem Medjaher, Ali Khenniche, Feteh Allah Isnasni

引用次数: 0

The Features of the Course of Traumatic Brain Disease in Persons with Combat Traumatic Brain Injury 作战创伤性脑损伤患者创伤性脑疾病病程特点

American Journal of Clinical and Experimental Medicine Pub Date : 2023-01-09 DOI: 10.11648/j.ajcem.20231101.12

Chernenko Inna

引用次数: 0

Different Neurological Pathologies Found in Humans Can Be Modelled into Mice Brains 在人类身上发现的不同的神经病理可以被模拟到老鼠的大脑中

American Journal of Clinical and Experimental Medicine Pub Date : 2023-01-09 DOI: 10.11648/j.ajcem.20221006.12

Emilio Guzmán Rojas

引用次数: 0

Effect of Radiotherapy on HB Level and Nutritional Status of Tumor Patients and Its Relationship with Hepcidin and EPO 放疗对肿瘤患者HB水平和营养状况的影响及其与Hepcidin和EPO的关系

American Journal of Clinical and Experimental Medicine Pub Date : 2021-11-12 DOI: 10.11648/J.AJCEM.20210906.11

Shan Tiantian, Cheng Zhen, Zuo Erdong, Yan Min, Pan Xiangtao

引用次数: 0

Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study IV期胃癌一线化疗后替加富-吉美拉西-奥特拉西维持治疗:一项回顾性研究

American Journal of Clinical and Experimental Medicine Pub Date : 2021-10-19 DOI: 10.11648/J.AJCEM.20210905.17

Kena Zhou, A. Zhao, Bin Wang, Jie Li, Yingyi Zhang, Meihong Wu, Xianbao Zhan

{"title":"Maintenance Therapy with Tegafur-gimeracil-oteracil After First-line Chemotherapy in Stage IV Gastric Cancer: A Retrospective Study","authors":"Kena Zhou, A. Zhao, Bin Wang, Jie Li, Yingyi Zhang, Meihong Wu, Xianbao Zhan","doi":"10.11648/J.AJCEM.20210905.17","DOIUrl":"https://doi.org/10.11648/J.AJCEM.20210905.17","url":null,"abstract":"Introduction: The feasibility, efficacy and safety of maintenance chemotherapy (MCT) after first-line therapy in advanced gastric cancer (AGC) remain obscure. This study aims to explore the efficacy and safety of tegafur-gimeracil-oteracil MCT in stage IV GC. Methods: Seventeen patients with stage IV GC had been involved in this study from the Department of Oncology of Changhai Hospital from January 1st, 2017 to August 31st, 2021. After 6-8 cycles of first-line chemotherapy with SOX (tegafur-gimeracil-oteracil combined with oxaliplatin) or DS (docetaxel combined with tegafur-gimeracil-oteracil) MCT was administered with tegafur-gimeracil-oteracil which continued until disease progression or intolerable adverse effects or death. The PFS, OS, DCR and adverse effects were analyzed. Results: Among 17 patients with stage IV GC, 11 patients received prior SOX-based first-line therapy, 6 patients with TS regimen. The best curative effect of first-line therapy were CR in 1 case, PR in 2 and SD in 14. DCR was 87.5% after tegafur-gimeracil-oteracil MCT, and the median PFS was 13.5 months, the median OS was 23 months. The main adverse effects of tegafur-gimeracil-oteracil MCT were grade 1-3 hematologic and grade 1 fatigue, gastrointestinal symptoms. There were no treatment-related deaths or toxic effects of grade 4.","PeriodicalId":404444,"journal":{"name":"American Journal of Clinical and Experimental Medicine","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133141903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Process Study on Surface Modification of Coral Hydroxyapatite 珊瑚羟基磷灰石表面改性工艺研究

American Journal of Clinical and Experimental Medicine Pub Date : 2021-10-12 DOI: 10.11648/J.AJCEM.20210905.15

Chang Jiahe, Su Jun, Zhang Wenyun

{"title":"Process Study on Surface Modification of Coral Hydroxyapatite","authors":"Chang Jiahe, Su Jun, Zhang Wenyun","doi":"10.11648/J.AJCEM.20210905.15","DOIUrl":"https://doi.org/10.11648/J.AJCEM.20210905.15","url":null,"abstract":"Objective: To explore process of modifying coral hydroxyapatite by nmZnO under different conditions, the final plan is to develop a porous artificial bone composite that combines the antibacterial properties of nano zinc oxide with the porous biodegradability of coral hydroxyapatite. Methods: Coral hydroxyapatite was modified by zinc nitrate sol-gel method at 70°C in weak acid environment. White granular porous composite materials were obtained by ultrasonic, rotary stirring, drying and calcination. The composition of the composite material is analyzed using X-ray diffractomer (XRD), using scanning electron microscopy (SEM) to observe and analyze changes in the surface appearance of composite materials, using energy dispersive X-ray spectroscopy (EDX) to observe and analyze the composition of the composite surface, the results of thermogravimetric analysis were used to study the decomposition temperature and other characteristics of the composite. Results: The sol-gel method can be used for antibacterial modification on CHA surface. When the mass ratio of coral hydroxyapatite, zinc nitrate and PEG-6000 is 48:4:5, the particle size and distribution of nano-zinc oxide particles are ideal, and uniformly distributed spherical ZnO nanoparticles can be observed under scanning electron microscopy. Conclusion: Coral hydroxyapatite surface could be modified by zinc nitrate sol-gel method. The particle size of nano zinc oxide is less than 100 nanometers. The agglomeration problem of nano-particles is solved; the porous structure of CHA are not destroyed.","PeriodicalId":404444,"journal":{"name":"American Journal of Clinical and Experimental Medicine","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123530425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0